PATENT CLAIM ANALYSIS

Application Number: 15994502
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-03
Patent Classification: ["514", "183000"]

Abstract:
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

Claim (Index 7):
The composition of  claim 1  wherein the therapeutic agent is bisantrene and the bisantrene is present in the composition in a drug conjugate form selected from the group consisting of:\n (a) a polymer system; \n (b) polylactides; \n (c) polyglycolides; \n (d) amino acids; \n (e) peptides; \n (f) multivalent linkers; \n (g) conjugates to fatty acids; \n (h) conjugates to fatty alcohols; \n (i) conjugates to elastin-like peptide; \n (j) conjugates with polyclonal or monoclonal antibodies, proteins, or peptides; \n (k) conjugates with cell-binding agents through a charged or pro-charged cross-linker; \n (l) conjugates to antibodies targeted to tumor markers; \n (m) biodegradable polymer-bioactive moiety conjugates; \n (n) conjugates with 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker; \n (o) conjugates with ladder frame polyether compounds, including those derived from brevenal, brevisin, tamulamide, brevetoxins, hemibrevetoxins, gambierols, and gambieric acids; \n (p) conjugates to antibodies having one or more non-natural amino acid residues at specific positions in the heavy or light chains; \n (q) conjugates to a sialoadhesin binding moiety; \n (r) pheophorbide-\u03b1 conjugates; \n (s) conjugates to multi-component nanochains; \n (t) conjugates to activatable antibodies that include a masking moiety, a cleavable moiety, and an antibody binding specifically to interleukin-6; \n (u) conjugates including hydrophilic linkers; \n (v) conjugates to antibodies specific for p97; \n (w) conjugates including a modified amino acid incorporating an azido group; \n (x) conjugates to albumin; and \n (y) conjugates to folate.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15979041', '14907728', '14907729', '13817096', '14250958']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8178491140549887
- 35 USC 102 Novelty (BERT): 0.5309988799575858
- Combined Prediction Score: 0.7891640906452485
- Mean Citation Score: 276.52593
- Max Citation Score: 362.98706
- Similarity Product: 245.9358742477

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test